The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

Sound ethical decision making is essential to astute and compassionate clinical care. Wise practitioners readily identify and reflect on the ethical aspects of their work. They engage, often intuitively and without much fuss, in careful habits—in maintaining therapeutic boundaries, in seeking consultation from experts when caring for patients who are difficult to treat or have especially complex conditions, in safeguarding against danger in high-risk situations, and in endeavoring to understand more about mental illnesses and their expression in the lives of patients of all ages, in all places, and from all walks of life. These habits of thought and behavior are signs of professionalism and help ensure ethical rigor in clinical practice.

Psychiatry is a specialty of medicine that, by its nature, touches on big moral questions. The conditions we treat often threaten the qualities that define human beings as individual, autonomous, responsible, developing, and fulfilled. Furthermore, these conditions often are characterized by great suffering, disability, and stigma, and yet individuals with these conditions demonstrate tremendous adaptation and strength. If all work by physicians is ethically important, then our work is especially so. As a service to Focus readers, this column provides ethics commentary on topics in clinical psychiatry. It also offers clinical ethics questions and expert answers in order to sharpen readers’ decision-making skills and advance astute and compassionate clinical care in the field.

Laura Weiss Roberts, M.D., M.A.

The population is aging. The term silver tsunami has now achieved cliché status for its colorful description of the impending, immense impact expected as the Baby Boomers age. Less discussed than the epidemiological and economic effects of this tsunami, however, are its “ethical waves” (1). Caring for older adults with psychiatric conditions brings an array of interesting and challenging ethical issues. For instance, aging adults with cognitive impairment may retain the capacity for some kinds of decisions and activities while lacking the capacity for others. Determining where to draw the line between capacity and impairment can be very difficult. Ethical dilemmas commonly involve tensions among cardinal ethical principles—for example, respect for persons (preserving individual worth and dignity), autonomy (upholding individual self-governance), beneficence (seeking to provide care that provides the greatest benefit, promoting clinical excellence), and nonmaleficence—primum non nocere (“first, do no harm”).

Additional key ethical principles also frequently come into play in working with older adults, including fidelity (faithfulness to the patient’s interests), veracity (the duty of truth and honesty), justice (fair treatment without prejudice), privacy (protection of patients’ personal information), and integrity—honorable conduct within the profession (2). For example, when should a psychiatrist reveal to third parties that an older adult has cognitive impairment severe enough that it affects her ability to perform routine daily tasks (veracity and privacy), when such a report will likely result in the restriction of the patient’s autonomy? How should a psychiatrist respond to a family’s request to sedate a cognitively impaired elder whose behaviors are troubling to the family (beneficence, nonmaleficence, and justice)? How should a psychiatrist attempt to balance the safety not only of the patient but also of other people (family members, caregivers, staff, the general public) when the patient’s behavior and lack of insight places himself and others at risk (respect for persons, fidelity, veracity, justice, privacy)?

This column provides two case illustrations of common yet challenging ethical dilemmas in geriatric psychiatry: determining when to intervene regarding a patient’s driving and managing severe behavioral disturbances in patients with dementia.

Case Illustration 1

Dr. J. is a 76-year-old Caucasian, retired economics professor from the small college town where you practice. He is accompanied by his wife, B., of 50 years and their daughter, H., for a follow-up appointment regarding depression. He has been in your clinic for four years for a history of depression, which he has battled since his young adulthood. Dr. J. reports that his mood has been stable on 10 mg escitalopram daily and 7.5 mg mirtazepine at bedtime for augmentation. He continues activities with his book club and playing tennis with other retired faculty. He is bright and social on examination. He was the sole breadwinner at home and is the oldest of three siblings. His father died in a nursing home as a result of the progressive loss of function. At this visit, he reports progressive and insidious difficulty with memory, particularly word finding and recalling short-term events. He has also noticed a decreased sense of smell and taste of food. There is no obvious tremor or rigidity on examination, and his gait is fluid without bradykinesia or shuffling. The Montreal Cognitive Assessment (MoCA), administered today, reveals a score of 22 out of 30 (with points missed on visuospatial/executive abilities and delayed recall; this is a decline from his previous score of 26 from two years ago).

He has remained independent in most activities, although his daughter notes that he has overdrawn his checking account three times this year, which he has never done before. Two weeks ago, he was seen in the emergency room for a near-syncope episode and required intravenous fluids for orthostasis. His wife noticed that he was short two days on his antihypertensive medication after this. According to his wife, he continues to drive, although she reports that recently she has grown more concerned about being in the car when he is driving, because he has been driving more slowly and sometimes misses turns. There have been no motor vehicle accidents, according to the patient and the wife, and he continues to shop, bathe, cook, and manage his activities of daily living (ADLs) independently. His daughter reports that he helps pick up her children from school before she comes home from work, although he has arrived late on several occasions this year, whereas previously he was very punctual. He reports that he is careful and that he has had no concerns driving.

1.1.

Which of the following pieces of evidence most strongly influences the psychiatrist’s determination of at-risk driving?

A.

Low MoCA score with impairments in both visuospatial/executive abilities and delayed recall

B.

The wife’s concerns about the patient’s driving ability

C.

The patient’s self-reported driving ability

D.

The patient’s independence

E.

Both A and B

1.2.

If you were Dr. J.’s psychiatrist, which one of the following would you be likely to recommend?

A.

File a report with the appropriate agency (e.g., Department of Public Health, Department of Motor Vehicles [DMV]) without telling the patient or family.

B.

Ask the wife to bring the patient to DMV for a driving test.

C.

Suggest to the daughter that she find someone else to drive her kids.

D.

Tell the patient he needs to stop driving or else you will report him.

E.

Refer Dr. J. to occupational therapy for a driving assessment; if the results are concerning, then inform the patient of the state-mandated reporting requirement and report him to state licensing authorities.

“America’s love affair with the automobile”—our enduring passion for cars, driving, the open road, and the freedom they symbolize—can present psychiatrists caring for older adults with challenging ethical dilemmas. Older adults are often reluctant to “retire” from driving. The emotional impact of this loss can be compounded by the difficulty in finding transportation when one doesn’t drive, especially because the infrastructure of many U.S. cities and towns depends heavily on the automobile for logistical activities.

The psychiatrist’s role in assessing the capacity to drive among individuals with neurocognitive disorders can create ethical tensions. Understandably, the idea of removing a prominent source of a patient’s sense of independence (and, often, a beloved activity) can be distressing to psychiatrists. The psychiatrist often feels caught in the intersection of principles of autonomy, beneficence, privacy, veracity, and fidelity. To complicate matters, many physicians are uncertain of their reporting responsibilities or feel that they lack the appropriate guidance and resources to handle this responsibility adequately (3).

There is a consistent agreement among physicians that individuals with moderate to severe neurocognitive disorders should not drive. However, there remains a great deal of debate about when individuals with mild cognitive impairment (MCI; or minor neurocognitive disorders) should retire from driving. At the margins—in cases in which the individual may still retain good social skills, family members do not report specific concerns, there is an absence of glaring evidence of impaired driving, but the individual shows clear signs of multidomain cognitive impairment—the psychiatrist needs some signposts for navigating this ethical dilemma.

Overall, individuals with dementia who drive are at increased risk of having a motor vehicle accident as the driver—with one study indicating that this risk may be highest in the several years preceding the dementia diagnosis (4). Moreover, other research has shown that individuals with neurocognitive disorders are at increased risk of driving slowly, not wearing seat belts, and having an elevated accident or collision risk (5). Several studies have demonstrated that, as neurocognitive disorders progress, the crash risk is significantly increased (6). Given the nebulous and, at times, fluctuating course of varying capacities of persons with neurodegenerative disease, it is no wonder that, in one study, most physicians reported not feeling competent to reliably determine driving safety (7).

There remains no definitive cognitive test or set of tests that can guide clinicians to determine a patient’s driving safety. The British Psychological Society considers on-road assessment the gold standard in assessing driving capacity (5). However, there are no controlled trials or prospective data to confirm that on-road or neuropsychological testing can reduce car accidents or support safe drivers to remain driving (8).

Several attempts have been made to aid physicians in identifying at-risk drivers. In 2010, the American Academy of Neurology published practice parameters for identifying at-risk drivers. The systematic review identified scores >.5 on the Clinical Dementia Rating scale, as well as the caregiver’s rating of a patient’s unsafe driving, as the highest level of evidence of identifying at-risk driving. In their report, a history of citations, crashes, reduced miles driven, or avoidance of driving; a Mini-Mental State Examination score of <24; and impulsive or aggressive personality traits were somewhat less useful in predicting driving risk; the patient’s self-report of driving ability was not useful (9). Recently, Rapoport et al. compiled a consensus recommendation for the assessment, identification, and reporting of individuals with MCI/mild dementia for providers (10). The authors recommended that caregiver concern about the patient’s driving, as well as abnormalities on the clock drawing test, a lower score on the MoCA, or a prior crash, should trigger a report to transportation authorities and/or a recommendation for specialized on-road testing. In addition, prolonged completion time for the Trail Making Test, Part B (with several errors), should also raise the consideration of reporting (10). Although there is mixed evidence regarding driving evaluations in terms of accident risk, Carr and O’Neill have suggested that there may be situations in which providers should consider referral for DMV or occupational therapist (often called driver rehabilitation specialists)–administered driving tests to stratify risk and inform driving retirement recommendations (11). The consensus remains that providers should weigh several aspects of the patient’s history and assessment to inform recommendations about driving cessation. Similarly, a recent Danish study argued for using the combination of the clinical interview, a neuropsychological battery, and a driving simulator to identify at-risk drivers more accurately (12). Carr and O’Neill have presented a reasonable approach to evaluating driving risk in aging adults with neurocognitive disorders, including questions that providers may ask to foster conversations about driving safety and techniques that family members could use to ensure that patients who are unsafe drivers no longer drive (13). Carr and O’Neill have also included several resources for providers and patients, including driving evaluation services and alternative transportation agencies.

The Case Continues

The patient undergoes an occupational therapy evaluation. On the basis of the results of this evaluation, the family’s report, and the psychiatrist’s own assessment, the psychiatrist files a report with DMV. The patient returns in one month, having received a notice from DMV stating that he may no longer drive. The patient is angry at the psychiatrist, stating that driving was a primary source of independence and pleasure for him. He does not recall that the psychiatrist informed him that he would have to report him to DMV. He asks the psychiatrist to contact DMV to try to get them to reverse the decision. The wife, who is in the room for this appointment, remains quiet but appears distressed.

1.3.

If faced with this situation, which of the following are you most likely to do?

A.

Recommend that the patient seek another opinion from a different psychiatrist.

B.

Speak to the wife privately, asking her for further information.

C.

Apologize and pretend to call DMV while the patient is in the office.

D.

Explain that, for the patient’s and other drivers’ safety, the psychiatrist is required to report when a patient has a cognitive impairment that may affect his or her driving ability.

In a survey of 239 physicians, several factors were predictors of the decision to address driving with patients, the strongest being the physician’s perception that addressing driving should be part of their role, as well as number of years in practice. Knowledge regarding the legal requirement to report to DMV was somewhat associated; moreover, physicians who were aware of the American Medical Association’s Physician’s Guide to Assessing and Counseling Older Drivers were significantly more likely to address the issue. Of note, physician specialty was not generally associated with a greater likelihood of addressing driving with patients (14).

The National Highway Traffic Safety Administration provides state-by-state information on physician reporting, in addition to a brief cognitive test called the Assessment of Driving-Related Skills, which assesses vision, cognition, and motor function (as well as the Trail-Making Test, Part B) but which the agency admits “does not predict crash risk.” Of note, states vary with respect to requirements for reporting to motor vehicle regulation boards. For instance, in California, physicians are considered mandated reporters and can be held liable for damages.

Although the intention in reporting individuals with neurocognitive disorders to regulating bodies such as DMV is to ensure the safety of the patient and his or her family, as well as that of fellow drivers and the general public, filing such reports and subsequent driving cessation do not come without consequence. Patients are often unhappy about the physician’s decision to report, and caregivers face additional burdens of transport and arranging activities (15). Despite unhappiness on the part of the patient or family members/caregivers, the physician’s ethical (and, in many cases, legal) obligation is to consider the patient’s and the public’s safety first. Referring the patient and family members to useful resources (see Box 1), as well as initiating these conversations early in the disease course, may help soften the blow.

Box 1: RESOURCES RELATED TO DRIVING AND NEUROCOGNITIVE DISORDERS

Alzheimer’s Association

Patient and family information regarding driving, as well as discussion of ethical considerations that may arise in neurocognitive disorders

http://www.alz.org/

http://www.alz.org/care/alzheimers-dementia-and-driving.asp

American Academy of Neurology

https://www.aan.com/Guidelines/home/ByTopic?topicId=15

Family Caregiver Alliance

https://www.caregiver.org/dementia-driving-and-california-state-law

The Hartford Center for Mature Market Excellence (several downloadable publications on driving and dementia)

https://www.thehartford.com/resources/mature-market-excellence/publications-on-aging

National Highway Traffic Safety Administration

http://www.nhtsa.gov/people/injury/olddrive/OlderDriversBook/pages/Contents.html

National Institute on Aging

https://www.nia.nih.gov/alzheimers/features/driving-and-dementia-health-professionals-can-play-important-role

Case Illustration 2

Mr. H. is a 78-year-old man with a major neurocognitive disorder resulting from Alzheimer’s disease (AD), which was diagnosed two years ago. He and his wife of 52 years live together and have three grown children, all of whom all live out of state. Mr. H.’s psychiatric symptoms have consisted of anxiety and occasional insomnia, and the couple has had no need for in-home assistance. His psychiatric medications have included only 10 mg donepezil per day, 20 mg memantine per day, and 50 mg trazodone at bedtime as needed. At today’s visit, Mrs. H. reports that Mr. H. has become increasingly difficult to redirect at home. He has started to accuse her of infidelity, and at times he becomes confused about her identity as his wife. Furthermore, he has begun to swear at her as often as several days per week over the past month. His insomnia has worsened so that Mrs. H. has taken to sleeping in another room. She reports hearing him pacing and talking at night, sometimes angrily. Mr. H. himself denies any problems with his mood or behavior. However, during the session, he appears irritable and gets up out of his chair repeatedly, needing to be redirected or distracted. At one point, when his wife tries to reassure him that “We’re here to get some help from the doctor,” Mr. H. states angrily, “I don’t need any help, and you sure aren’t helping! Let’s get out of here!” Mrs. H. manages to calm him down by changing the subject but looks very stressed herself. She becomes tearful and states, “I think I need something to knock him out, you know what I mean? I don’t know what else to do.”

2.1.

If faced with this situation as Mr. H.’s psychiatrist, which of the following are you most likely to do?

A.

Prescribe haloperidol, 2 mg as needed for agitation.

B.

Prescribe 50 mg quetiapine three times a day.

C.

Tell the wife to slip the patient extra trazodone at night, up to 200 mg.

D.

Tell the patient that he needs to behave or he will end up in a nursing home.

E.

Discuss the importance of nonpharmacologic approaches to managing the patient’s behavior.

Patients with dementia commonly experience behavioral and psychological symptoms, including depressive symptoms, anxiety, irritability, sleep problems, psychotic symptoms, and agitation. The term behavioral and psychological symptoms of dementia is now used to encompass the full range of noncognitive symptoms of people with dementia. These symptoms are thought to occur nearly universally among people with dementia at some point during the illness (16).

Severe forms of behavioral disturbance have been described since Dr. Alois Alzheimer’s initial report of the disease’s characteristics. Since that time, agitation, delusions, and hallucinations have been noted to be common—perhaps even core—symptoms of the disease (17). The literature has repeatedly confirmed a substantial prevalence of delusions and hallucinations (17). Ropacki and Jeste provided a systematic review of psychotic symptoms in people with AD in diverse settings (18). They reported a median prevalence of psychotic symptoms as follows: any psychosis, 41.1% (range 12.2%–74.1%); hallucinations, 18% (range 4%–41%); delusions, 36% (range 9.3%−63%); and other psychotic symptoms (such as misidentification), 25.6% (range 3.6%−38.9%). Thus, psychotic symptoms are quite common for people with AD.

Aggressive behavior can also be further defined as either physical (including hitting, kicking, scratching, or biting) or nonphysical (pacing, wandering, or disrobing). Furthermore, patients also may exhibit inappropriate verbal behavior, such as screaming or swearing. Some recent studies have found that over half of dementia patients exhibit some of these signs at a given time (16, 19), and other reports describe a risk after two years of almost 100% (20).

The morbidity associated with agitation, aggression, and psychosis is significant. Not only do these symptoms cause indignity to the patient and jeopardize the safety and well-being of caregivers, they also appear to be predictors of more rapid cognitive decline, institutionalization, and hastened death (21). Caregiver burden related to these symptoms is such a major problem that caregiver health is often affected.

The Case Continues

Mrs. H. enrolls the patient in a local adult day program, which he attends five days per week. For approximately six months, Mr. H. is more able to control his behavior at home. Mrs. H. attends a caregiver support group and learns skills for managing the patient’s outbursts, and she appreciates the supportive environment. However, Mr. H.’s functioning declines further; he is becoming increasingly confused and requires more help with bathing, feeding, grooming, and toileting than Mrs. H. can provide. She and her children make the difficult decision to place him in a residential care facility three miles from their home. Within the first week, the facility calls the psychiatrist, stating that the patient is hitting staff when they try to help him with routine care, is yelling out for hours at a time, and is up most of the night. The facility is asking for medication to help manage the patient’s behavior.

2.2.

If faced with this situation, which of the following are you likely to do?

A.

Prescribe quetiapine, 50 mg as needed.

B.

Ask the facility to transfer the patient to the nearest emergency room so that the patient can be given emergency medication

C.

Inquire as to the behavioral interventions they have tried, such as refraining from demands on the patient when he is out of control—then prescribe low doses of a sedating medication to address the acute situation.

D.

Never prescribe an antipsychotic medication in this situation, due to the “black box” warnings about prescribing this class of medications to patients with dementia.

2.3.

The following medications have been found to be modestly effective in the treatment of episodic agitation and assaultiveness in patients with dementia EXCEPT:

A.

Anticonvulsants, such as valproate

B.

Low-dose second-generation antipsychotic medications, such as quetiapine and risperidone

C.

Selective serotonin reuptake inhibitor medications, such as citalopram

D.

Low-dose benzodiazepines

Although studies have found that some medications have modest effectiveness in the treatment of some of these behaviors (17), there is no Food and Drug Administration–approved medication regimen. First-line therapy should be nonpharmacologic to address the patient’s environment and caregiving supports, and clinicians should evaluate and address underlying medical etiologies of the behavior (22, 23). Recently published, the American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia recommends nonemergent (i.e., routine or scheduled) use of these medications only “when symptoms are severe, are dangerous, and/or cause significant distress to the patient” (24).

The guidelines also stress the importance of weighing potential risks and benefits (including the possibility of no or limited benefit) of antipsychotic medication and discussing these “with the patient (if clinically feasible) and with the patient’s surrogate decision maker (if relevant) with input from family or others involved with the patient” (24). The guidelines further emphasize the importance of discussing alternatives with the family or other caregivers to ensure full support with any decision involving pharmacologic approaches.

When the patient is experiencing severe distress, when the patient’s and others’ safety is a primary concern, and when alternative strategies have been attempted without any improvement, then pharmacologic approaches can be ethically justified on the basis of beneficence (attempting to improve the patient’s quality of life), although the tension with nonmaleficence remains. Given the potential risks of antipsychotic and other off-label uses of psychotropic medications in treating behavioral disturbances in dementia, psychiatrists should conduct a thorough discussion of risks, benefits, and alternatives with the surrogate decision maker (unless the patient can provide consent, which is almost never the case in such scenarios). Protecting others (family and/or caregiving staff and other providers) from an aggressive patient should also factor into the clinician’s ethical considerations. Finally, veracity and fidelity—ensuring that the family understands not only the goals of treatment but also the limits of what we know about treating these symptoms and remaining faithful to the patient’s interests while balancing these against other concerns—remain paramount.

Answers

1.1

The answer is E. According to expert consensus and current guidelines, the opinion of caregivers is very useful in predicting at-risk driving. In addition, several experts argue that the use of impaired neuropsychological screening tests (a low MoCA score in this case) in addition to the caregiver’s (Mr. H.’s wife’s) concerns should raise suspicion for at-risk driving.

1.2

The answer is E. In some situations, it is helpful to stratify patients’ driving risk in bolstering a recommendation toward retirement of driving, although there is no true gold-standard test to predict crash risk. If the psychiatrist practices in a state with mandated reporting, informing the patient of the psychiatrist’s concerns and decision to report to DMV accomplishes two goals. First, this fulfills the ethical obligations of nonmaleficence and beneficence by intervening to decrease the risk of injury to the patient and to other drivers. Second, informing the patient honors veracity and fidelity and therefore may aid in strengthening the therapeutic alliance.

1.3

The answer is D. As discussed above, the psychiatrist’s duty as a physician is to fulfill both beneficence and nonmaleficence for the sake of the patient as well as other drivers. Discussing this with the patient may help to strengthen the therapeutic alliance.

2.1

The answer is E. Nonpharmacologic approaches targeting agitation should be attempted before medications are prescribed. Identification of potential underlying factors that may be contributing should be part of the initial assessment of the patient, and the treatment plan should be formed around any potentially contributory factors. Caregiver education, support groups for caregivers, and specific training in behavioral interventions that can ameliorate the patient’s symptoms should be included as part of the initial treatment plan.

2.2

The answer is C. When a patient moves to a residential facility, there often is a period of severe disorientation, given that previous routines and visual cues have been disrupted. This transition may result in more severe behavioral problems, which may wane over time. A well-trained staff may be knowledgeable in helping to attenuate behavioral outbursts by working with family and with the patient on the source of the outbursts. Often, the behaviors are most out of control around hygiene issues, which, in part, may be the result of anxiety and fear. In this case, with the presumption that the staff is kind, attentive, and understanding of these issues, a low dose of a medication needs to be considered to aid in patient care. It is exceedingly important to ensure the safety of the staff, who cannot care well for an individual of whom they are afraid.

2.3

The answer is D. Although any of these medications may have severe side effects, even low-dose and short-acting benzodiazepines increase the risk of delirium and falling, which would preclude their use at this stage of the patient’s illness, until all other possibilities have failed to help him.

Dr. O’Connell, Dr. Sommer, and Dr. Dunn are with the Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA (e-mail: ).

The authors report no financial relationships with commercial interests.

References

1 Dunn LB, Alici Y: Ethical waves of the silver tsunami: consent, capacity, and surrogate decision-making. Am J Geriatr Psychiatry 2013; 21:309–313CrossrefGoogle Scholar

2 Roberts LW, Hoop JG, Dunn LB: Ethical aspects of psychiatry; in American Psychiatric Publishing Textbook of Psychiatry, 5th ed. Edited by Hales RE, Yudofsky SD, Gabbard GO. Washington, DC, American Psychiatric Publishing, 2008Google Scholar

3 Betz ME, Jones J, Carr DB: System facilitators and barriers to discussing older driver safety in primary care settings. Inj Prev 2015; 21:231–237CrossrefGoogle Scholar

4 Meuleners LB, Ng J, Chow K, et al.: Motor vehicle crashes and dementia: a population-based study. J Am Geriatr Soc 2016; 64:1039–1045CrossrefGoogle Scholar

5 Carter K, Monaghan S, O’Brien J, et al.: Driving and dementia: a clinical decision pathway. Int J Geriatr Psychiatry 2015; 30:210–216CrossrefGoogle Scholar

6 Breen DA, Breen DP, Moore JW, et al.: Driving and dementia. BMJ 2007; 334:1365–1369CrossrefGoogle Scholar

7 Jones K, Rouse-Watson S, Beveridge A, et al.: Fitness to drive - GP perspectives of assessing older and functionally impaired patients. Aust Fam Physician 2012; 41:235–239Google Scholar

8 Martin AJ, Marottoli R, O’Neill D: Driving assessment for maintaining mobility and safety in drivers with dementia. Cochrane Database Syst Rev 2013; 8:CD006222Google Scholar

9 Iverson DJ, Gronseth GS, Reger MA, et al.: Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1316–1324CrossrefGoogle Scholar

10 Rapoport MJ, Naglie G, Herrmann N, et al.: Developing physician consensus on the reporting of patients with mild cognitive impairment and mild dementia to transportation authorities in a region with mandatory reporting legislation. Am J Geriatr Psychiatry 2014; 22:1530–1543CrossrefGoogle Scholar

11 Carr DB, O’Neill D: Mobility and safety issues in drivers with dementia. Int Psychogeriatr 2015; 27:1613–1622CrossrefGoogle Scholar

12 Piersma D, Fuermaier AB, de Waard D, et al.: Prediction of fitness to drive in patients with Alzheimer’s dementia. PLoS One 2016; 11:e0149566CrossrefGoogle Scholar

13 Carr DB, Ott BR: The older adult driver with cognitive impairment: “It’s a very frustrating life”. JAMA 2010; 303:1632–1641CrossrefGoogle Scholar

14 Adler G, Rottunda SJ: The driver with dementia: a survey of physician attitudes, knowledge, and practice. Am J Alzheimers Dis Other Demen 2011; 26:58–64CrossrefGoogle Scholar

15 Chacko EE, Wright WM, Worrall RC, et al.: Reactions to driving cessation: a qualitative study of people with dementia and their families. Australas Psychiatry 2015; 23:496–499CrossrefGoogle Scholar

16 Savva GM, Zaccai J, Matthews FE, et al.: Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 2009; 194:212–219CrossrefGoogle Scholar

17 Koppel J, Greenwald BS: Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions. Neuropsychiatr Dis Treat 2014; 10:2253–2262CrossrefGoogle Scholar

18 Ropacki SA, Jeste DV: Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005; 162:2022–2030CrossrefGoogle Scholar

19 Lyketsos CG, Steinberg M, Tschanz JT, et al.: Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708–714CrossrefGoogle Scholar

20 Wetzels RB, Zuidema SU, de Jonghe JF, et al.: Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. Am J Geriatr Psychiatry 2010; 18:1054–1065CrossrefGoogle Scholar

21 Scarmeas N, Brandt J, Blacker D, et al.: Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 2007; 64:1755–1761CrossrefGoogle Scholar

22 Cohen-Mansfield J, Mintzer JE: Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord 2005; 19:37–40CrossrefGoogle Scholar

23 Gitlin LN, Kales HC, Lyketsos CG: Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012; 308:2020–2029CrossrefGoogle Scholar

24 American Psychiatric Association: The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Washington, DC, American Psychiatric Publishing, 2015. http://dx.doi.org/10.1176/appi.books.9780890426807Google Scholar